CTOs on the Move

Acucela

www.acucela.com

 
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.acucela.com
  • 1301 2nd Ave # 1900
    Seattle, WA USA 98101
  • Phone: 206.805.8300

Executives

Name Title Contact Details

Similar Companies

Nymox

NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.

University of Vermont - College of Medicine

University of Vermont - College of Medicine is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

YMCA of Southern Maine

The Y: Were for youth development, healthy living, and social responsibility

Cherry County Hospital

Cherry County Hospital is a hospital and healthcare provider.

D4C Dental Brands

D4C Dental Brands, Inc. focuses exclusively on supporting pediatric dental practices and orthodontic practices. We support general dentists to primarily work on teens, but 85-90% of the doctors we support are pediatric or orthodontic specialists. Our offices are beautifully decorated and designed for patient and parent comfort.